CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Olopatadine/mometasone

combination drug

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionFeb 16, 2025
Entity authorityQ97738461 ↗
Source-derived summary

Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. It contains olopatadine hydrochloride and mometasone furoate monohydrate. It is sprayed into the nose.

Common side effects include an unpleasant taste (dysgeusia).

It was approved for medical use in Australia in December 2019, and in the United States in January 2022.

Editorial summary

The public source identifies “Olopatadine/mometasone” as combination drug. This brief keeps that definition visible, then builds a research path around Olopatadine, mometasone and combination.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current lead gives the account dated anchors—2019, 2022—that can be checked directly. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with Olopatadine, mometasone and combination providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “Olopatadine/mometasone”, the useful work is to connect “combination drug” to the records capable of establishing context and consequence.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Feb 16, 2025. The linked authority identifier is Q97738461. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2019 and 2022.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Olopatadine/mometasone”, its source revision and the description used here.
  2. Expand the search: follow Olopatadine/mometasone primary sources, Olopatadine/mometasone archive and Olopatadine research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Olopatadine/mometasone”?
  2. Which cited source is closest to the event, object or claim?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Olopatadine/mometasone” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.